Analyst consensus rating
Arrowhead Pharmaceuticals Analyst Rating: none
ARWR is rated none by 11 analysts with a $110.18 target. As of 2026-08-27.
Direct answer
Arrowhead Pharmaceuticals's consensus rating is none.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $110.18.
Forecast evidence checked August 27, 2026.
Get free Arrowhead Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $89.12
- Average price target
- $110.18
- High price target
- $126.00
- Low price target
- $100.00
- Low target gap
- +12.2%
- Target upside
- +23.6%
- High target gap
- +41.4%
- Target range width
- 29.2%
- Consensus rating
- none
- Analysts
- 11
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $110.18.
How far are Arrowhead Pharmaceuticals's low and high targets from the recorded price?
The low target implies +12.2%, while the high target implies +41.4%.
How many analysts are included in Arrowhead Pharmaceuticals's consensus?
The verified consensus includes 11 analysts.
How is Arrowhead Pharmaceuticals's target upside or downside calculated?
The average target of $110.18 is divided by the recorded price of $89.12, then one is subtracted to produce +23.6%. This does not guarantee a future return.
When was Arrowhead Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.